HDR UK Gateway
HDR Gateway logo

Bookmarks

ID 212-3: Estimating inequalities in burden of illness in patients with Alzheimer’s disease

Safe People

Organisation name

Lane Clark & Peacock LLP

Applicant name(s)

Funders/ Sponsors

Safe Projects

Project ID

ID 212-3

Lay summary

Understanding the impact of Alzheimer’s disease on individuals and on the healthcare system will support the development of interventions and treatments to reduce the progression of Alzheimer’s disease.

Public benefit statement

With current trends in population ageing, the number of people living with Alzheimer’s disease has increased substantially in recent years and is expected to continue increasing. These older persons experience a wide range of negative impacts on their health as both a direct and indirect consequence of a reduction in memory, and changes in thinking and behaviour. As a result, healthcare providers such as the National Health Service are facing an increasing challenge in supporting patients to live Alzheimer’s disease with many patients having to self-fund specialist care due to a lack of support. Understanding the impact of Alzheimer’s disease on individuals and on the healthcare system will support the development of interventions and treatments to reduce the progression of Alzheimer’s disease. This is particularly challenging in Alzheimer’s disease given the variety in the course of the illness and the many conditions indirectly associated with Alzheimer’s disease. This complexity is best assessed through the analysis of large-scale health databases (such as Discover-NOW) that contain a rich variety of data. We will use Discover-Now to develop robust epidemiological analyses and statistical models that will improve our understanding of the health profiles of people living with Alzheimer’s disease and the potential impact of new treatments being developed to reduce the risk of Alzheimer’s disease progression. By repeating our analysis across important subgroups of groups we will aim to identify the populations with highest unmet need and who might benefit most from treatment. These findings can help to ensure that new treatments are developed that support Alzheimer’s disease patients with the highest unmet health needs, resulting in more equitable health outcomes for the population.

Other approval committees

Latest approval date

14/09/2023

Safe Data

Dataset(s) name

Safe Setting

Access type

TRE

Safe Outputs

Link to research outputs